Insomnia evaluation and treatment

Lying awake or waking too early can affect concentration and make bedtime feel frustrating. An Ondoc licensed clinician can assess sleep patterns and discuss CBT-I and medication options; Insurance or $50 self-pay.

Get care for insomnia online

Tell us what you need.

Sleep evaluation
Insurance or self-pay?

What your visit can cover

  • Sleep schedule and contributing medicines, mood symptoms, or apnea risks reviewed
  • CBT-I referral or behavioral plan focused on persistent insomnia
  • Discuss medication benefits, risks and contributing conditions

When to be seen in person

Loud snoring, witnessed breathing pauses, or major daytime sleepiness warrants assessment for sleep apnea. Seek urgent mental health care for little sleep with unusually high energy or unsafe behavior, and do not drive while drowsy.

About Insomnia

Insomnia means difficulty falling asleep, staying asleep or waking too early despite enough opportunity to sleep, with daytime effects. Chronic insomnia usually occurs at least three nights a week for at least three months. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first treatment for persistent insomnia; it addresses sleep habits and the worry and behaviors that keep sleep problems going. Snoring with breathing pauses may indicate sleep apnea, a different problem. Ondoc can review sleep patterns, medicines and contributing conditions, discuss a treatment plan and refer for CBT-I or sleep assessment.

NHLBI: insomnia treatment

AASM: pharmacologic treatment of chronic insomnia

Additional medication information

Educational options, not an offer of a prescription from every provider. No dose or ordering instruction is provided.

Eszopiclone (Lunesta)
FDA-approved for insomnia and can help falling asleep and staying asleep. It is a controlled medicine; complex sleep behaviors and next-day impairment are important risks.
Doxepin for insomnia
The low-dose insomnia formulation is FDA-approved for difficulty staying asleep. Higher-dose antidepressant formulations have different indications.
Ramelteon (Rozerem)
FDA-approved for insomnia involving difficulty falling asleep. It acts on melatonin receptors and is not a controlled substance.
Mirtazapine (Remeron)
FDA-approved for major depression, not insomnia. It may help sleep when depression is present; sleep use is off-label, and increased appetite, weight gain and sedation can occur.
Quetiapine (Seroquel)
Used for schizophrenia and bipolar disorder; extended-release quetiapine also has an adjunctive depression indication. Sleep use is off-label, not an established treatment for uncomplicated chronic insomnia. Sedation may help sleep in some patients treated for these conditions, but metabolic and movement effects matter.
Other FDA-approved insomnia options
Zolpidem and zaleplon are controlled sleep medicines; suvorexant, lemborexant and daridorexant are controlled orexin-receptor antagonists. Their sleep indications and risks differ, and your provider decides whether any is appropriate.
Reference only. Not a substitute for medical advice. Not appropriate for emergencies.
Medically reviewed by Dr. Ikechukwu Ogbu, MD